Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Pomalyst
|
| gptkbp:activities |
proteasome inhibitor
|
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:brand |
gptkb:Velcade
|
| gptkbp:class |
boronic acid derivative
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I newly diagnosed multiple myeloma relapsed multiple myeloma relapsed mantle cell lymphoma |
| gptkbp:contraindication |
pregnancy
breastfeeding severe hepatic impairment hypersensitivity to bortezomib |
| gptkbp:discovered_by |
gptkb:Millennium_Pharmaceuticals
|
| gptkbp:financial_performance |
stable for 24 hours at room temperature after reconstitution
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
bortezomib
|
| gptkbp:ingredients |
C19 H25 Boron N4 O4
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 X X24
|
| gptkbp:is_monitored_by |
liver function tests
renal function blood counts neurological status |
| gptkbp:is_used_for |
gptkb:healthcare_organization
mantle cell lymphoma |
| gptkbp:manager |
intravenous
subcutaneous |
| gptkbp:marketed_as |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Janssen_Pharmaceuticals |
| gptkbp:pharmacokinetics |
inhibits proteasome activity
induces apoptosis in cancer cells half Life 9-15 hours |
| gptkbp:research_areas |
biomarkers
cancer therapy combination therapy drug resistance hematologic malignancies |
| gptkbp:side_effect |
fatigue
nausea diarrhea peripheral neuropathy thrombocytopenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
NF-k B pathway
|
| gptkbp:type_of |
179324-69-7
|